Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Fineline Cube Feb 13, 2026
Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Fineline Cube Feb 13, 2026
Company Deals

Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline

Fineline Cube Feb 13, 2026
Company Deals

Ribo Life Science Licenses $4.4 Billion MASH siRNA Portfolio to Madrigal Pharmaceuticals

Fineline Cube Feb 12, 2026
Company Deals

Novartis Secures Long-Term Actinium-225 Supply from Niowave for Radioligand Therapy Expansion

Fineline Cube Feb 12, 2026
Policy / Regulatory

FDA Cracks Down on Compounded GLP-1 APIs; Novo Nordisk Sues Hims & Hers for Patent Infringement

Fineline Cube Feb 11, 2026
Company Drug

Amgen’s UPLIZNA Wins European Approval for Generalized Myasthenia Gravis

Fineline Cube Feb 13, 2026
Company Drug

Innovent Biologics Initiates Phase 3 HeriCare-Breast01 Study for IBI354 in HER2+ Breast Cancer

Fineline Cube Feb 13, 2026
Company Drug

AffaMed Therapeutics’ Luminate Receives Clinical Trial Approval for Dry AMD in China

Fineline Cube Sep 26, 2023

AffaMed Therapeutics, a China-based biotech firm, has announced the receipt of its first clinical trial...

Company Drug

Hansoh Pharmaceutical Gets NMPA Approval for HS-20105 Clinical Study in Solid Tumors

Fineline Cube Sep 26, 2023

Hansoh Pharmaceutical Group Co., Ltd (HKG: 3692), a China-based pharmaceutical company, has announced that it...

Drug

Shanghai Junshi’s Tuoyi Meets Primary Efficacy Endpoint in Phase III Melanoma Study

Fineline Cube Sep 26, 2023

Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in...

Company Drug

Abbisko Therapeutics Gets NMPA Approval for Irpagratinib Combination Study in HCC

Fineline Cube Sep 26, 2023

Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has received approval from the National...

Policy / Regulatory

CDE Introduces New Guidelines for Generic Drug Quality and Efficacy Consistency Evaluation

Fineline Cube Sep 26, 2023

The Center for Drug Evaluation (CDE) has released a new set of Guidelines for “the...

Company Drug

Hepagene Therapeutics’ HPG7233 Receives US FDA IND Approval for NASH Treatment

Fineline Cube Sep 25, 2023

Hong Kong-based biopharmaceutical company Hepagene Therapeutics Inc. has announced that the US Food and Drug...

Company Drug

Abbisko Therapeutics’ Irpagratinib Receives FDA Clearance for Phase I Study in HCC

Fineline Cube Sep 25, 2023

Shanghai-based biotechnology company Abbisko Therapeutics Co., Ltd (HKG: 2256) has announced that it has received...

Company Drug

Sino Biopharmaceutical Submits IND Application for AT2R Antagonist TRD205 to FDA

Fineline Cube Sep 25, 2023

Sino Biopharmaceutical Ltd (HKG: 1177), a leading China-based biotech company, has announced the filing of...

Company Drug

Fosun Pharma’s Serplulimab Approved for Esophageal Squamous Cell Carcinoma and Grafalon for GvHD Study

Fineline Cube Sep 25, 2023

Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has issued updates on the development statuses...

Company

J&J and HHS Expand Public Health Initiative with Asha Therapeutics

Fineline Cube Sep 25, 2023

Johnson & Johnson (J&J; NYSE: JNJ) and the US Department of Health and Human Services...

Company Drug

CDC Provisionally Recommends Pfizer’s Abrysvo for Maternal Immunization Against RSV

Fineline Cube Sep 25, 2023

The US Centers for Disease Control and Prevention (CDC) has issued a provisional recommendation for...

Company Drug

Boehringer Ingelheim and Eli Lilly’s Jardiance Wins FDA Approval for CKD Prevention

Fineline Cube Sep 25, 2023

Boehringer Ingelheim (BI) and Eli Lilly (NYSE: LLY) have received regulatory approval from the US...

Company Drug

MSD’s Keytruda Meets Endpoints in Urothelial Carcinoma Trial but Misses in NSCLC Study

Fineline Cube Sep 25, 2023

Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading global pharmaceutical company, last week released...

Company Drug

Betta Pharmaceuticals’ CFT8919 Accepted for Review by China’s NMPA for EGFR L858R Solid Tumors

Fineline Cube Sep 25, 2023

Betta Pharmaceuticals Co., Ltd (SHE: 300558), a China-based pharmaceutical company, has announced that the National...

Company

Simcere Pharmaceutical Reports 25.2% Revenue Growth in 2023 Interim Financials

Fineline Cube Sep 25, 2023

China-based Simcere Pharmaceutical Group (HKG: 2096) has released its interim financial report for 2023, revealing...

Company

3D Medicines’ H1 2023 Report Highlights 70.3% YOY Growth in Envafolimab Sales

Fineline Cube Sep 25, 2023

China-based oncology specialist 3D Medicines (HKG: 1244) has released its financial report for the first...

Company Medical Device

Acotec Scientific Holdings Receives Japanese Marketing Approval for Peripheral Support Catheter Vericor

Fineline Cube Sep 25, 2023

Acotec Scientific Holdings Ltd (HKG: 6669), a China-based medical device company, has announced that it...

Company Deals

Chime Biologics Partners with Panolos Bioscience to Speed Up Multi-Specific Protein Development

Fineline Cube Sep 25, 2023

China-based Contract Development and Manufacturing Organization (CDMO) Chime Biologics Ltd has announced a strategic cooperation...

Company Deals

Hangzhou Qihan Biotechnology Secures Over $13.8 Million in Pre-Series B Financing

Fineline Cube Sep 25, 2023

Hangzhou Qihan Biotechnology Co., Ltd, a leading xenotransplantation specialist based in China, has reportedly raised...

Company Drug

CNIPA Upholds Alynlam Pharmaceutical’s PCSK9 siRNA Patent Against Junshi Biosciences Challenge

Fineline Cube Sep 25, 2023

The China National Intellectual Property Administration (CNIPA) has rejected a challenge filed by Junshi Biosciences...

Posts pagination

1 … 426 427 428 … 624

Recent updates

  • China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China
  • Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh
  • Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise
  • Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity
  • Immunofoco Bio Files Hong Kong IPO for Solid Tumor CAR-T Pipeline
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

China Medical System Licenses Teikoku’s Lidoderm for Postherpetic Neuralgia in China

Company

Organon Reports 2025 Revenue Decline to $6.2 Billion; JADA Sale and Portfolio Pressures Weigh

Company Deals

Salubris Pharma Files Hong Kong IPO for Secondary Listing to Expand Cardiorenal Metabolic Franchise

Company

Sanofi Appoints Belén Garijo as New CEO to Drive R&D Innovation and Productivity

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.